| abstract |
The present invention relates to compounds of formula (I) wherein R 1 denotes hydrogen or halogen, R 2 denotes hydrogen, halogen, lower alkyl or lower alkoxy, R 1 and R 2 may together with two ring carbons denote -CH = CH-CH = CH -, R3 denotes halogen, trifluoromethyl, lower alkyl or lower alkoxy, R4 / 4 denotes independently hydrogen or lower alkyl, R5 denotes lower alkyl, lower alkoxy, amino, phenyl, hydroxy-lower alkyl, cyano-lower alkyl, carbamoyl -lower alkyl, pyridyl, pyrimidyl, - (CH2) n-piperazinyl, which is optionally substituted with one or more lower alkyl groups or hydroxy-lower alkyl, then means - (CH2) n-morpholinyl, - (CH2) n- piperidinyl, - (CH2) n + 1-imidazolyl, lower alkylsulfanyl, lower alkylsulfonyl, benzylamino, -NH- (CH2) n + 1-N (R4 ") 2, - (CH2) n + 1-N (R4 ") 2, -O- (CH2) n + 1-morpholinyl, -O- (CH2) n + 1-piperidinyl or -O- (CH2) n + 1-N (R4") 2, wherein R4 "denotes hydrogen or lower alkyl and is 0-2, X denotes -C (O) N (R4") - or -N (R4 ") C (O) -, and pharmaceutically acceptable acids thereof ske addition salt. The above-mentioned compounds have been shown to have good affinity for the NK-1 receptor and can therefore be used to treat diseases associated with this receptor. |